The Compounding Pharmacy, Hickory, NC
Is The Compounding Pharmacy registered with the FDA as a 503B outsourcing facility?
No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility.
Does The Compounding Pharmacy hold a North Carolina pharmacy license?
State board of pharmacy records for North Carolina are not checked: the board’s website refused automated requests with an access error, and this index does not work around blocks.
Has The Compounding Pharmacy had a state board action or FDA letter?
FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 warning letter (Jun 5, 2020) for The Compounding Pharmacy. State board of pharmacy records for North Carolina are not checked: the board’s website refused automated requests with an access error, and this index does not work around blocks.
FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.
- Names in FDA records
- The Compounding Pharmacy
- Location
- Hickory, NC
- Type as FDA labels it
- 503A
- FDA 503B list
- No matching record found
- Form 483s on FDA’s actions page
- 2
- Warning letters on FDA’s actions page
- 1
- Latest action on that page
- Sep 29, 2021
- FDA Data Dashboard inspections
- 2 inspections: 2 OAI; 1 published Form 483
- Form 483 text on this page
- 1 Form 483, 3 observations
- State board records
- Not checked
FDA inspections and letters
FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as The Compounding Pharmacy, a 503A facility, with 3 dated actions.
| Document | |||
|---|---|---|---|
| Sep 29, 2021 | Form 483 | 483 Issued 09/29/2021 | fda.gov |
| Jun 5, 2020 | Warning letter | Warning Letter (06/05/2020) | FDA copy (archived) |
| Apr 8, 2019 | Form 483 | 483 Issued 04/08/2019 | Not linked by FDA |
A Form 483 lists investigator observations, not a final FDA determination. A warning letter states FDA’s view when it was issued, not a court finding; any close-out letter FDA lists is a row of its own.
FDA inspection classifications and published Form 483s
The FDA Data Dashboard, read Nov 15, 2026, lists The Compounding Pharmacy, Hickory, NC (FEI number 3009127876), matched to this page by exact name, city and state. It lists 2 inspections: 2 OAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.
| Inspection ended | Classification | Project area and product type | FEI | Inspection ID |
|---|---|---|---|---|
| Sep 29, 2021 | Official Action Indicated (OAI) | Drug Quality Assurance (Drugs) | 3009127876 | 1157754 |
| Apr 8, 2019 | Official Action Indicated (OAI) | Drug Quality Assurance (Drugs) | 3009127876 | 1085558 |
Form 483s FDA has published for this site
- Sep 29, 2021: Form 483 to The Compounding Pharmacy, published Mar 14, 2022. fda.gov
FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.
Form 483 observations
A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.
FDA’s published Form 483 for this site has 3 numbered observations in all. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.
Inspection Sep 29, 2021: 3 observations
- Firm on the cover
- , 750 4th St SW The Compounding Pharmacy, Manufactur e r-Sterile/non-Sterile Compounding Pharmacy Hickory, NC 28602-3401
- FEI number
- 3009127876
- FDA district office on the cover
- Not read
- Matched to this page by
- FEI number on the cover; linked from actions page, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.
Observation 1
Your facility design allowed the influx of poorer quality air into a higher classified area.
Specifically,
ted B4> and <Redacted B4> (classified ISO 7) contain a mini-split type of air condit ioning (AC) unit. The presence of this equipment, containing a condenser and fan, within or in close enough proximity to the ISO 5 area could compromise the air in the ISO 5 area as they are particle generati ng equipment that cannot be sufficiently cleaned inside and do not provide for HEPA filtration of ai r moving into the classified space.
Redacted B4> clean
room <Redac
a)<
b)the hole for the drain tube removing condensation from the mini-split air conditioning (AC) unit in c leanroom <
Redacted B4> had air movement from the hole. This shows a connection between the open back of the AC unit in the ISO 7 area surrounding the ISO 5 hood, and the unclassified space in which the hole terminates. There is a gap between the top edge of the AC unit in clean
room <Redacted B4> and the wall which may further indicate an unsealed connection on the back of the AC unit. ...
Observation 2
The classified aseptic processing areas had difficult to clean and/or visibly dirty equipment or surface.
Specifically,
and <Redacted B4> (classified ISO 7) are surrounded on three sides with foil tape that contains adhesive to the edge. This tape is not cleanroom grade and the adhesive presents its own hazard by its non-cleanable nature. The edge of the tape appears to be darker than the tape itself, and there is evidence of water leakage from under the tape potentially providing an ideal environment for microbial growth.
Redacted B4>
a)the AC units in cleanrooms <
b) your environmental monitoring process does not sample the AC units or the surrounding tape, and your procedures do not specifically call out that the units are cleaned.
ed B4> and <Redacted B4> contain a mini-split type of air conditioni ng (AC) uni t. The equipment, containing a condenser and fa n i nside the units, are not cleanable without disa ssembly and therefore are difficult to clean.
Redacted B4> clean
room <Redact
c)<
Redacte d B4> (approximately 0.5 -1cm) does not all ow for clea ning of the wall via a smooth easily cleanable surface.
d)the gap at the back of the AC unit in cleanroom <
Observation 3
Non-depyrogenated equipment was used in sterile drug production.
Specifically, glassware used in the compounding of product intended to be sterile (including <Redac t ed B4> products) was place d in a <Redacted B4> for depyrogenation. There is no assurance that that glassware was depyrogenated due to the lack of endotoxin indicators used in the batch of glassware. This affects all products compounded in the pre-sterile room.
Furthermore, your report of values from 8/30/2021 on the <Redac ted B4> used to depyrogenate gl assware for compounding sterile produ ct show s <Redacted B4> of test points as being <Redacted B4> with an average of <Redacted B4>.
State board of pharmacy records
State board of pharmacy records for North Carolina are not checked: the board’s website refused automated requests with an access error, and this index does not work around blocks.
This page restates FDA’s lists. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.
Sources
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA Registered Outsourcing Facilities (503B)
- FDA Data Dashboard: inspection classifications and published Form 483s
- FDA: FDA Form 483 Frequently Asked Questions
Records last pulled Nov 15, 2026. Every entry links to the original public record.